Previous close | 0.5800 |
Open | 0.5500 |
Bid | 0.5400 x N/A |
Ask | 0.5700 x N/A |
Day's range | 0.5400 - 0.5500 |
52-week range | 0.2900 - 0.8000 |
Volume | |
Avg. volume | 60,322 |
Market cap | 60.908M |
Beta (5Y monthly) | 1.17 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.20 |
TORONTO, May 28, 2024--Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the formation of a Clinical Advisory Board comprised of distinguished clinical research leaders and experts in drug development in genetic muscle disorders, including Duchenne muscular dystrophy (DMD or Duchenne).
TORONTO, May 14, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held today, May 14, 2024 (the "Meeting").
TORONTO, May 14, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today its financial results and operational highlights for the three months ended March 31, 2024. All references to currency in this press release are in Canadian dollars unless otherwise noted.